Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topotecan and Lapatinib in Recurrent Ovarian or Peritoneal Cancer
NCT00888810Phase 2Terminated
- Sponsor
- Centre François Baclesse
- Start
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lapatinib in Malignant Ovarian Tumor, primary peritoneal cancer (PPC) and fallopian tube adenocarcinoma, sponsored by Centre François Baclesse. Primary endpoint: Global Response Rate. Started Mar 2008; status: terminated.
02
Drugs
lapatinib
03
Conditions
Malignant Ovarian Tumorprimary peritoneal cancer (PPC)fallopian tube adenocarcinoma
Beyond the preview
Go deeper on NCT00888810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00888810.